Navigation Links
Xeomin® (incobotulinumtoxinA) Data To Be Presented At The 71st Annual Assembly Of The American Academy Of Physical Medicine And Rehabilitation
Date:11/5/2010

inum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of XEOMIN.

ADVERSE REACTIONSCervical Dystonia:  The most commonly observed adverse reactions (incidence ≥10% of patients and twice the rate of placebo) for XEOMIN 120 Units and XEOMIN 240 Units, respectively, were: dysphagia (13%, 18%), neck pain (7%, 15%), muscle weakness (7%, 11%), and musculoskeletal pain (7%, 4%).

Blepharospasm: The most common adverse reactions (incidence ≥10% of patients and twice the rate of placebo) for XEOMIN were eyelid ptosis (19%), dry mouth (16%), visual impairment (12%), diarrhea (8%), and headache (7%).

DRUG INTERACTIONSConcomitant treatment of XEOMIN and aminoglycoside antibiotics, spectinomycin, or other agents that interfere with neuromuscular transmission (e.g., tubocurarine-like agents), or muscle relaxants, should be observed closely because the effect of XEOMIN may be potentiated.

USE IN PREGNANCYPregnancy Category C: There are no adequate and well-controlled studies in pregnant women. XEOMIN should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Please see full prescribing information for XEOMIN, including Boxed WARNING, available at www.XEOMIN.com. About MerzMerz Pharmaceuticals, LLC is a part of the Merz Group of companies and was established in 1995 to develop and commercialize products for the Merz Group. Areas of therapeutic focus include Neurology, Dermatology, and Podiatry.

With a 102 year heritage, the Merz Group is known worldwide for its development of original compounds and formulations for medical professionals and consumers in 90 countries. Globally, Merz is a leader in the development of pharmaceuticals for the treatment of neurological and psycholo
'/>"/>

SOURCE Merz Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Xeomin® (incobotulinumtoxinA) - a Botulinum Toxin Free From Accessory Proteins - Now Available in the U.S.
2. FDA Approves Merz Pharmaceuticals Xeomin® (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm
3. Romark Announces Data Presented at AASLD Meeting 2010
4. Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD
5. ANA598 Data Presented at AASLD Highlight Positive Clinical Profile of DAA Entering Phase IIb
6. Over 20 New Clinical Studies Presented on Masimo Noninvasive Patient Monitoring Technologies at the American Society of Anesthesiologists Annual Meeting
7. New Analysis of CAMBIA™ Pivotal Data to be Presented at the 4th World Congress on Controversies in Neurology
8. Positive Results From LigoCytes Norovirus Vaccine Challenge Study Presented at IDSA Annual Meeting
9. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
10. Celsion Announces ThermoDoxs Prominence in Abstracts Presented at the 2nd International MR-Guided Ultrasound Symposium
11. New FORTEO® and EVISTA® Data to be Presented at Premiere Scientific Meeting for Bone and Mineral Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015 /OFF HOLD ... LLC, PIV757417 The following release: "Biotech Advancements Coupled ... Products & Treatments for Critical-Care Patients With Severe ... 3 Aug 2015 12:30 GMT Cooperative ... surgical research and top-tier universities for identifying biotech ...
(Date:8/3/2015)... Aug. 3, 2015  Charleston Laboratories, Inc., an ... second clinical development program with a Phase 1 ... CL-H1T contains fast-dissolving promethazine and sumatriptan.  ... a treatment for migraine headache pain and migraine-induced ... patients with migraine headaches also suffer from nausea ...
(Date:8/3/2015)... , August 3, 2015 BiondVax Pharmaceuticals ... statistical analysis of results from a study which demonstrates that ... II trial which took place in 2012, provided participants with ... the time of the study- in particular the current newly ... the United States in 2015. ...
Breaking Medicine Technology:/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 3/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 4/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 5/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 6Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3
(Date:8/3/2015)... ... ... opinion piece published July 28 by the Washington Post, the conventional wisdom that ... not be accurate. While this system may work for some people, the author notes that ... on the individual and at what point that person is in their weight loss journey. ...
(Date:8/3/2015)... ... , ... Bayer has agreed to pay $56.9 million to set up a ... to have suffered an arterial blood clot including stroke and heart attack. The litigation ... has been ongoing for well-over five years. In 2009, lawsuits filed against Bayer involving ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... finalist in 2015 MarketingProfs Bright Bulb B2B Awards. , The MarketingProfs Bright Bulb ... for B2B brands. BESLER Consulting's campaign for the launch of their Readmissions Analytics ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... contract research organisations (CROs) for a slew of benefits, allowing them to gain ... operations, boost quality with cost-effective utilisation of resources, get access to innovation and ...
(Date:8/3/2015)... ... 2015 , ... A recent survey by the National ... believe people can positively affect their diabetes, few look beyond diet changes to ... changes was important. Far fewer participants mentioned the need for exercise (30%), maintaining ...
Breaking Medicine News(10 mins):Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4
... for Provider Profiling, Predictive Modeling, Resource Management and ... DST Health Solutions today announced the ... DSTHS RiskAnalyzer(TM). RiskAnalyzer uses claims experience to determine ... under the Centers for Medicare and Medicaid Services ...
... QHR hospital clients received unexpected checks totaling nearly ... ranging from $65,000 to more than $750,000 - ... a unique and innovative partnership between the hospital ... Under the QHR/Gallagher Retro Insurance Program, hospital groups ...
... cadherin superfamily has a correlate relationship with the ... suggested that, unlike E-cadherin, N-cadherin may promote motility ... pathological significance of E-cadherin and N-cadherin expressions in ... led by Prof. Qing-Xia Fan from China detected ...
... 100,000 Swedes are under treatment with the blood-thinning drug ... makes the initiation of treatment a risky balancing act ... Uppsala University have developed a model for calculating the ... in the scientific publication New England Journal of ...
... PURCHASE, N.Y., Feb. 19 The PepsiCo Foundation ... Save the Children to help ensure the survival ... and Bangladesh, which together are home to 40 ... )With support from the PepsiCo Foundation, Save ...
... 19 Cardium Therapeutics (NYSE Alternext US: CXM) ... on January 23, 2009 has been accepted by ... Stock Exchange). (Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO )As ... from the staff of its current listing exchange ...
Cached Medicine News:Health News:DST Health Solutions Launches New RiskAnalyzer Software to Help Medicare Advantage Plans Manage Risk Adjustment 2Health News:DST Health Solutions Launches New RiskAnalyzer Software to Help Medicare Advantage Plans Manage Risk Adjustment 3Health News:QHR, Gallagher Partnership Yields More Thank $4 Million for QHR Hospital Clients 2Health News:Knowledge of genetics improves uncertain medication 2Health News:PepsiCo Foundation Announces Grant to Save the Children to Address Malnutrition in Developing Nations 2Health News:PepsiCo Foundation Announces Grant to Save the Children to Address Malnutrition in Developing Nations 3Health News:Cardium's Exchange Listing Compliance Plan Accepted by NYSE Alternext US 2Health News:Cardium's Exchange Listing Compliance Plan Accepted by NYSE Alternext US 3Health News:Cardium's Exchange Listing Compliance Plan Accepted by NYSE Alternext US 4Health News:Cardium's Exchange Listing Compliance Plan Accepted by NYSE Alternext US 5
... use, the z-boxTM is designed to bring ... business model behind the z-boxTM is designed ... most flexible way to bring this technology ... to run procedure specific software in many ...
NOW Legionella is an immunochromatographic membrane assay to detect Legionella pneumophila serogroup 1 soluble antigen in human urine....
ThyroTest TSH is a rapid, qualitative test for hypothyroidism screening in adults....
... The BinaxNOW Influenza A & B ... easiest flu test on the market ... between influenza A and influenza B ... test. Now you can focus on ...
Medicine Products: